All Mark Cavendish: Page 2
-
Cav dodges questions, but Petacchi could haunt Omega leadout
- By Gregor Brown
- Published May. 2, 2013
Former world champion says the failed signing of Italian sprinter isn't a distraction, but his leadout could be impacted
-
After early hiccups, Omega Pharma backs Cav at the Giro
- By VeloNews.com
- Published Apr. 30, 2013
Belgian squad backs Manxman in his bid for stage wins
-
Spring Classics: Winners and losers
- By Neal Rogers
- Published Apr. 22, 2013
- Updated Apr. 22, 2013 at 11:28 AM EDT
Fabian Cancellara and a slew of first-time winners came out on top in the classics, but who didn't?
-
Varied fortunes for the cobbled kings
- By Ryan Newill
- Published Apr. 9, 2013
- Updated Apr. 9, 2013 at 1:22 PM EDT
Spartacus reigned on the cobbles, but hundreds of storylines carried through the 2013 northern classics
-
Bling, bling: Kittel gets back on track at Scheldeprijs
- By Matthew Beaudin
- Published Apr. 3, 2013
Big German successfully defends his 2012 title by going faster than speed demon Mark Cavendish
-
Explained: How the UCI calculates team points
- By Steve Maxwell
- Published Mar. 29, 2013
The way in which the UCI calculates points for pro teams is complicated, but recent changes have made it more transparent
-
Kristoff seizes De Panne lead with TT on tap
- By VeloNews.com
- Published Mar. 28, 2013
As expected, Peter Sagan and Tom Boonen abandon as they prepare for Sunday's Tour of Flanders
-
Cavendish wins tough sprint at De Panne
- By VeloNews.com
- Published Mar. 27, 2013
- Updated Mar. 27, 2013 at 1:45 PM EDT
Manxman follows fiery, early leadout to victory in the win in Koksijde
-
Sagan says Boonen is a favorite to win Flanders
- By Matthew Beaudin
- Published Mar. 27, 2013
Belgian rider has battled injuries and setbacks all season, including a crash in Sunday's Ghent-Wevelgem
-
Sagan: Impossible to control?
- By Matthew Beaudin
- Published Mar. 27, 2013
- Updated Mar. 29, 2013 at 7:42 PM EDT
Peter Sagan's ability to win in seemingly any terrain and under any circumstance is proving difficult to manage for Omega Pharma